Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Non-Current Assets for 5 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 466.42% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 42.93% increase, with the full-year FY2024 number at $148537.0, down 49.75% from a year prior.
  • Non-Current Assets was $1.1 million for Q3 2025 at Inhibikase Therapeutics, up from $58605.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.1 million in Q3 2025 to a low of $2783.0 in Q1 2021.
  • A 5-year average of $318834.6 and a median of $260264.0 in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 743.87% in 2023, then crashed 73.84% in 2025.
  • Inhibikase Therapeutics' Non-Current Assets stood at $2783.0 in 2021, then surged by 20208.12% to $565175.0 in 2022, then crashed by 47.7% to $295599.0 in 2023, then tumbled by 49.75% to $148537.0 in 2024, then surged by 612.22% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Non-Current Assets are $1.1 million (Q3 2025), $58605.0 (Q2 2025), and $116564.0 (Q1 2025).